Tekmira, BMS broaden lipid nanoparticle collaboration for RNAi delivery
This article was originally published in Scrip
Executive Summary
The Canadian firm Tekmira Pharmaceuticals, which hopes that its lipid nanoparticle (LNP) delivery technology can eventually enable multiple clinical candidates for effective RNA interference ("gene silencing"), has expanded its current multiyear collaboration with Bristol-Myers Squibb. It will now review LNP formulations in cancer.